BNP Paribas Asset Management
KYMR icon

BNP Paribas Asset Management’s Kymera Therapeutics KYMR Stock Holding History

BNP Paribas Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.37M Sell
64,467
-308
-0.5% -$24.4K 0.01% 848
2025
Q4 		$5.04M Buy
64,775
+64,363
+15,622% +$4.35M 0.01% 838
2025
Q3 		$23K Buy
412
+69
+20% +$3.11K ﹤0.01% 1324
2025
Q2 		$15K Buy
+343
New +$11.8K ﹤0.01% 1620

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

BNP Paribas Asset Management's KYMR Position: Q1 2026 in Review

BNP Paribas Asset Management reduced its Kymera Therapeutics (KYMR) stake by 0.48% in Q1 2026, selling an estimated $24.4K and leaving 64,467 shares worth $5.37M. The position accounts for 0.01% of the portfolio, ranked #848.

BNP Paribas Asset Management first reported a position in KYMR in Q2 2025 and has held it in 4 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • BNP Paribas Asset Management held 64,467 shares of Kymera Therapeutics worth $5.37M as of Q1 2026.
  • BNP Paribas Asset Management sold 308 Kymera Therapeutics shares in Q1 2026, an estimated $24.4K.
  • Kymera Therapeutics made up 0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #848 holding.
  • BNP Paribas Asset Management first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.